Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$2.1 million.

  • Lineage Cell Therapeutics' Gains from Investment Securities was N/A to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year change of. This contributed to the annual value of -$2.1 million for FY2024, which is 4040.74% down from last year.
  • As of FY2024, Lineage Cell Therapeutics' Gains from Investment Securities stood at -$2.1 million, which was down 4,040.74% from $54,000 recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Gains from Investment Securities high stood at $367,000 for FY2022, and its period low was -$2.1 million during FY2024.
  • Over the past 3 years, Lineage Cell Therapeutics' median Gains from Investment Securities value was $54,000 (recorded in 2023), while the average stood at -$569,000.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Gains from Investment Securities soared by 1,629.17% in 2022, and later tumbled by 4,040.74% in 2024.
  • Lineage Cell Therapeutics' Gains from Investment Securities (Yearly) stood at $20,000 in 2020, then tumbled by 220.00% to -$24,000 in 2021, then spiked by 1,629.17% to $367,000 in 2022, then tumbled by 85.29% to $54,000 in 2023, then slumped by 4,040.74% to -$2.1 million in 2024.